<DOC>
	<DOCNO>NCT00483990</DOCNO>
	<brief_summary>The main objective study determine safety tolerability repeat application PSD502 glans penis healthy male volunteer</brief_summary>
	<brief_title>Phase I Study PSD502 ( Lidocaine Prilocaine Spray ) Applied Glans Penis Three Times Day 21 Days Healthy Male Volunteers</brief_title>
	<detailed_description>This phase I , double-blind , stratify , parallel group , placebo-controlled repeat dose study minimum 8 circumcise 8 uncircumcised healthy male volunteer . Subjects attend 2 study visit , 1 Screening Visit ( Visit 1 ) , consecutive 21-day treatment visit ( Visit 2 ; Days 1-21 ) commences 14 day Screening visit . Subjects reside phase I unit throughout treatment period . The duration subject 's participation study 5 week . Subjects stratify base whether circumcise uncircumcised within stratify group subject randomize PSD502 ( lidocaine prilocaine spray ) placebo 3:1 ratio . Procedures 21 day treatment period include : visual examination glans penis , blood sample collection pharmacokinetic analysis lidocaine prilocaine , swab glans penis residual PSD502 , vital sign 12-lead ECG , adverse event enquiry collection concomitant medication . Subjects discharge clinic Day 21 follow safety evaluation .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Prilocaine</mesh_term>
	<mesh_term>EMLA</mesh_term>
	<criteria>Willing able provide write informed consent Male , age 18 year In generally good health opinion Investigator Willing able comply study procedure opinion Investigator History significant medical condition would preclude study participation , opinion Investigator . Currently take , take within 2 week prior Screening Visit , concomitant medication could confound interpretation safety data PSD502 Suffering STD , positive hepatitis B , hepatitis C , HIV infection . Safety test abnormality Screening Visit , particular liver function test , indicative medical condition would preclude participation , opinion Investigator . Significant abnormality glans penis would preclude interpretation examination glans , could worsen use PSD502 . History alcohol drug abuse within 1 year prior Screening visit . Known drug sensitivity amidetype local anesthetic . Use investigational ( nonregistered drug within 30 day Screening Visit . Unlikely understand able comply study procedure , reason , opinion Investigator . History Glucose6Phosphate Dehydrogenase ( G6PD ) deficiency use medication would increase susceptibility methemoglobinemia ( e.g . antimalarial agent ) . Use class 1 ( e.g . mexiletine , tocainide ) III ( e.g . amiodarone , sotaolol ) antiarrhythmic drug .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Phase I Study healthy subject</keyword>
</DOC>